First Time Loading...

Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390

Watchlist Manager
Guizhou Xinbang Pharmaceutical Co Ltd Logo
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Watchlist
Price: 3.96 CNY 1.02% Market Closed
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one Guizhou Xinbang Pharmaceutical Co Ltd stock under the Base Case scenario is 9.32 CNY. Compared to the current market price of 3.96 CNY, Guizhou Xinbang Pharmaceutical Co Ltd is Undervalued by 58%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
9.32 CNY
Undervaluation 58%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.2
P/S
P/S
Price to Sales
1.2
vs History
85
vs Industry
67
Median 3Y
1.5
Median 5Y
1.5
Industry
2.4
Forward
1.1
More Details
33.2
P/E
P/E
Price to Earnings
33.2
vs History
74
vs Industry
15
Median 3Y
40.9
Median 5Y
40.9
Industry
22.9
Forward
27.1
More Details
9.7
P/OCF
P/OCF
Price to OCF
9.7
vs History
74
vs Industry
37
Median 3Y
19.6
Median 5Y
15
Industry
17.1
More Details
93.6
P/FCFE
P/FCFE
Price to FCFE
93.6
vs History
11
vs Industry
7
Median 3Y
18.3
Median 5Y
18.3
Industry
23.2
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
92
vs Industry
59
Median 3Y
1.4
Median 5Y
1.7
Industry
2.1
More Details
1.2
EV/S
EV/S
Enterprise Value to Sales
1.2
vs History
92
vs Industry
68
Median 3Y
1.7
Median 5Y
1.7
Industry
2.6
Forward
1.1
More Details
6.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.6
vs History
92
vs Industry
33
Median 3Y
8.7
Median 5Y
8.7
Industry
5.1
More Details
21.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
21.5
vs History
71
vs Industry
18
Median 3Y
28.7
Median 5Y
25.6
Industry
13.6
Forward
13.1
More Details
21.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
21.5
vs History
71
vs Industry
22
Median 3Y
28.7
Median 5Y
25.6
Industry
17
Forward
15.8
More Details
10.1
EV/OCF
EV/OCF
Enterprise Value to OCF
10.1
vs History
80
vs Industry
37
Median 3Y
21.2
Median 5Y
16.4
Industry
15.8
More Details
12
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12
vs History
87
vs Industry
28
Median 3Y
32.1
Median 5Y
23.1
Industry
17.6
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
92
vs Industry
59
Median 3Y
1.3
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Guizhou Xinbang Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
7.6B CNY 1.2 33.2 21.5 21.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
697.9B USD 20.5 133.2 60.2 69.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.2 33 36
US
Johnson & Johnson
NYSE:JNJ
357.8B USD 4.4 8.8 11.8 15.5
US
Merck & Co Inc
NYSE:MRK
323.8B USD 5.3 140.4 33.4 53
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.3 140.6 225.6
CH
Novartis AG
SIX:NOVN
179.8B CHF 4.2 13.3 9.7 16.1
CH
Roche Holding AG
SIX:ROG
172.7B CHF 2.9 15 8.6 10.2
US
Pfizer Inc
NYSE:PFE
155.7B USD 2.7 73.5 11 16.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.